WASHINGTON — U.S. officials granted full approval to a closely watched Alzheimer's drug on Thursday, clearing the way for Medicare and other insurance plans to cover the treatment for people with the brain-robbing disease.
The Food and Drug Administration endorsed the IV drug, Leqembi, for patients with mild dementia and other symptoms caused by early Alzheimer's disease. It's the first medicine that's been convincingly shown to modestly slow the cognitive decline caused by Alzheimer's.
Japanese drugmaker Eisai received conditional approval from the FDA in January based on early results suggesting Leqembi worked by clearing a sticky brain plaque linked to the disease.
The FDA confirmed those results by reviewing data from a larger, 1,800-patient study in which the drug slowed memory and thinking decline by about five months in those who got the treatment, compared to those who got a dummy drug.
Biden says his economic agenda helps red states
The ins and outs of enrolling in Medicare while on Social Security disability
Advisor News
- The Gen Z money paradox
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
- Election results cloud retirement legislation outlook, experts say
- Planning for the missing chapter
More Advisor NewsAnnuity News
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- Boomers want retirement protection, but their actions don’t match their mindset
- NAIC task force to address LTC riders
- ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
- Jackson Launches Direct-to-Consumer Annuity Offering
More Annuity NewsHealth/Employee Benefits News
- Vermont public schools expect the lowest health insurance increase in years. For districts, it’s only a small relief.
- Vt. public schools expect the lowest health insurance increase in years
- Samantha Wildow: Mercy Health warns thousands of Medical Mutual of Ohio patients may go out-of-network in 2027
- Reports Outline Managed Care Study Results from Harvard University (Inpatient-Only List Removals Shifted Procedures To The Outpatient Setting And Reduced Medicare Spending): Managed Care
- Health and Humor: Picking a Medicare insurance plan is daunting
More Health/Employee Benefits NewsLife Insurance News
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- U-Haul Holding Company to Participate in Deutsche Bank Conference
- NAIC task force to address LTC riders
- Protective names Kurt Meyers Chief Legal Officer and Fernando Levy Chief Digital & AI Officer
- Best’s Commentary: Shanghai Cross-Border Investment Pilot Unlocks Overseas Growth Potential of China Non-Life Companies
More Life Insurance News